Rua Bioscience Limited (NZE:RUA)

Rua Bioscience Statistics

Total Valuation

Rua Bioscience has a market cap or net worth of NZD 8.30 million. The enterprise value is 8.86 million.

Market Cap	8.30M
Enterprise Value	8.86M

Important Dates

The next estimated earnings date is Wednesday, November 26, 2025.

Earnings Date	Nov 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Rua Bioscience has 244.04 million shares outstanding. The number of shares has increased by 23.01% in one year.

Current Share Class	244.04M
Shares Outstanding	244.04M
Shares Change (YoY)	+23.01%
Shares Change (QoQ)	+37.64%
Owned by Insiders (%)	21.92%
Owned by Institutions (%)	3.46%
Float	171.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.54
PB Ratio	1.70
P/TBV Ratio	3.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.56
EV / Sales	4.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.17

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.16.

Current Ratio	1.24
Quick Ratio	0.33
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	-0.29
Interest Coverage	-20.83

Financial Efficiency

Return on equity (ROE) is -59.29% and return on invested capital (ROIC) is -33.06%.

Return on Equity (ROE)	-59.29%
Return on Assets (ROA)	-28.71%
Return on Invested Capital (ROIC)	-33.06%
Return on Capital Employed (ROCE)	-67.66%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.25
Inventory Turnover	1.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.26% in the last 52 weeks. The beta is 0.22, so Rua Bioscience's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-16.26%
50-Day Moving Average	0.05
200-Day Moving Average	0.03
Relative Strength Index (RSI)	34.42
Average Volume (20 Days)	143,140

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Rua Bioscience had revenue of NZD 1.83 million and -3.46 million in losses. Loss per share was -0.02.

Revenue	1.83M
Gross Profit	850,074
Operating Income	-3.33M
Pretax Income	-3.46M
Net Income	-3.46M
EBITDA	-3.00M
EBIT	-3.33M
Loss Per Share	-0.02

Balance Sheet

The company has 241,421 in cash and 803,995 in debt, giving a net cash position of -562,574 or -0.00 per share.

Cash & Cash Equivalents	241,421
Total Debt	803,995
Net Cash	-562,574
Net Cash Per Share	-0.00
Equity (Book Value)	4.89M
Book Value Per Share	0.02
Working Capital	452,527

Cash Flow

In the last 12 months, operating cash flow was -2.79 million and capital expenditures -3,431, giving a free cash flow of -2.79 million.

Operating Cash Flow	-2.79M
Capital Expenditures	-3,431
Free Cash Flow	-2.79M
FCF Per Share	-0.01

Margins

Gross margin is 46.54%, with operating and profit margins of -182.57% and -189.19%.

Gross Margin	46.54%
Operating Margin	-182.57%
Pretax Margin	-189.19%
Profit Margin	-189.19%
EBITDA Margin	-164.02%
EBIT Margin	-182.57%
FCF Margin	n/a

Dividends & Yields

Rua Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.01%
Shareholder Yield	-23.01%
Earnings Yield	-41.65%
FCF Yield	-33.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Rua Bioscience has an Altman Z-Score of -7.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.6
Piotroski F-Score	3